{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:03:30Z","timestamp":1781816610308,"version":"3.54.5"},"reference-count":74,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cell Coolab Ostrava\u2014Research and Development Center for Cell Therapy in Hematology and Oncology","award":["CZ.02.1.01\/0.0\/0.0\/17_049\/0008440"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/17_049\/0008440"]}]},{"name":"New Directions of Biomedical Research in the Ostrava Region","award":["CZ.02.1.01\/0.0\/0.0\/18_069\/0010060"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/18_069\/0010060"]}]},{"name":"Institutional Development Plan of University of Ostrava, allocated by The Ministry of Education, Youth and Sports","award":["IRP03_2018-2020"],"award-info":[{"award-number":["IRP03_2018-2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Cellular immunotherapy is becoming a new pillar in cancer treatment after recent striking results in different clinical trials with chimeric antigen receptor T cells. However, this innovative therapy is not exempt from challenges such as off-tumor toxicity, tumor recurrence in heterogeneous tumors, and affordability. To surpass these limitations, we exploit the unique anti-tumor characteristics of natural killer (NK) cells. In this study, we aimed to obtain a clinically relevant number of allogeneic NK cells derived from peripheral blood (median of 14,050 million cells from a single donor) to target a broad spectrum of solid and liquid tumor types. To boost their anti-tumor activity, we combined allogeneic NK cells with the approved anti-cluster of differentiation 38 (CD-38) monoclonal antibody Daratumumab to obtain a synergistic therapeutic effect against incurable multiple myeloma. The combination therapy was refined with CD16 polymorphism donor selection and uncomplicated novel in vitro pretreatment to avoid undesired fratricide, increasing the in vitro therapeutic effect against the CD-38 positive multiple myeloma cell line by more than 20%. Time-lapse imaging of mice with established human multiple myeloma xenografts revealed that combination therapy of selected and pretreated NK cells with Daratumumab presented tumor volumes 43-fold smaller than control ones. Combination therapy with an allogeneic source of fully functional NK cells could be beneficial in future clinical settings to circumvent monoclonal antibodies\u2019 low therapeutic efficiency due to NK cell dysfunctionality in MM patients.<\/jats:p>","DOI":"10.3390\/cells10050967","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T12:47:07Z","timestamp":1619009227000},"page":"967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-0918","authenticated-orcid":false,"given":"Benjamin","family":"Motais","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Faculty of Science, University of Ostrava, 701 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-4696","authenticated-orcid":false,"given":"Sandra","family":"Charv\u00e1tov\u00e1","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Faculty of Science, University of Ostrava, 701 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Walek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"PrimeCell Advanced Therapy, Inc., 708 52 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-2825","authenticated-orcid":false,"given":"Matou\u0161","family":"Hrdinka","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1131-289X","authenticated-orcid":false,"given":"Ryszard","family":"Smolarczyk","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44 102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Cicho\u0144","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44 102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Czapla","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44 102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National, Research Institute of Oncology, Gliwice Branch, 44 102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-2723","authenticated-orcid":false,"given":"Michal","family":"\u0160im\u00ed\u010dek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Faculty of Science, University of Ostrava, 701 00 Ostrava, Czech Republic"},{"name":"Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Jel\u00ednek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"\u0160ev\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Faculty of Science, University of Ostrava, 701 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Sobotka","sequence":"additional","affiliation":[{"name":"Spadia LAB, a.s., Fren\u0161t\u00e1t pod Radho\u0161t\u011bm, 700 30 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Ko\u0159\u00edstek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-4048","authenticated-orcid":false,"given":"Juli R.","family":"Bag\u00f3","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"},{"name":"Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"ref_1","first-page":"725","article-title":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia","volume":"374","author":"Porter","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2005.02.006","article-title":"T cell immunity and graft-versus-host disease (GVHD)","volume":"5","author":"Ichiki","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e36688","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.it.2013.10.007","article-title":"Tumoricidal activity of human dendritic cells","volume":"35","author":"Tel","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/icb.2010.78","article-title":"Activating and inhibitory receptors of natural killer cells","volume":"89","author":"Pegram","year":"2010","journal-title":"Immunol. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Motais, B., Charv\u00e1tov\u00e1, S., Hrdinka, M., \u0160im\u00ed\u010dek, M., Jel\u00ednek, T., \u0160ev\u010d\u00edkov\u00e1, T., Ko\u0159\u00edstek, Z., H\u00e1jek, R., and Bag\u00f3, J.R. (2020). A Bird\u2019s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers, 12.","DOI":"10.3390\/cancers12051333"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cell.2017.11.037","article-title":"Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor","volume":"172","author":"Barrow","year":"2018","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.bbmt.2018.12.317","article-title":"First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed\/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma","volume":"25","author":"Bachanova","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2018.36.15_suppl.8006","article-title":"Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma","volume":"36","author":"Shah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5507\/bp.2018.064","article-title":"Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected \u201creal-world\u201d population","volume":"163","author":"Minarik","year":"2019","journal-title":"Biomed. Pap."},{"key":"ref_20","first-page":"379123","article-title":"Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity","volume":"2011","author":"Alderson","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1182\/blood.V126.23.4237.4237","article-title":"Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma","volume":"126","author":"Jenkins","year":"2015","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"srep43873","DOI":"10.1038\/srep43873","article-title":"Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function","volume":"7","author":"Veluchamy","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2005.08.004","article-title":"Flow cytometric assay for determination of FcgammaRIIIA-158 V\/F polymorphism","volume":"306","author":"Bottcher","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Karimi, M.A., Lee, E., Bachmann, M.H., Salicioni, A.M., Behrens, E.M., Kambayashi, T., and Baldwin, C.L. (2014). Measuring Cytotoxicity by Bioluminescence Imaging Outperforms the Standard Chromium-51 Release Assay. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089357"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1479-5876-9-184","article-title":"High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis","volume":"9","author":"Benevolo","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00251-002-0526-9","article-title":"Analysis of HLA-E expression in human tumors","volume":"54","author":"Pedrinaci","year":"2003","journal-title":"Immunogenetics"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Felices, M., Lenvik, A.J., McElmurry, R., Chu, S., Hinderlie, P., Bendzick, L., Geller, M.A., Tolar, J., Blazar, B.R., and Miller, J.S. (2018). Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight, 3.","DOI":"10.1172\/jci.insight.96219"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V","article-title":"Prognostic value of intratumoral natural killer cells in gastric carcinoma","volume":"88","author":"Ishigami","year":"2000","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","article-title":"The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma","volume":"79","author":"Coca","year":"1997","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(01)00292-6","article-title":"Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer","volume":"35","author":"Villegas","year":"2002","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","article-title":"Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands","volume":"68","author":"Wendel","year":"2008","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"839684","DOI":"10.1155\/2015\/839684","article-title":"Chemokine Receptor Expression on Normal Blood CD56+NK-Cells Elucidates Cell Partners That Comigrate during the Innate and Adaptive Immune Responses and Identifies a Transitional NK-Cell Population","volume":"2015","author":"Lima","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fmed.2017.00092","article-title":"Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response","volume":"4","author":"Nardy","year":"2017","journal-title":"Front. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4161\/onci.1.1.17963","article-title":"Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy","volume":"1","author":"Hubert","year":"2012","journal-title":"OncoImmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-04-0850","article-title":"Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism","volume":"10","author":"Niwa","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_41","first-page":"1840","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2010","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"Bakker","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/1097-0142(196611)19:11<1743::AID-CNCR2820191143>3.0.CO;2-U","article-title":"Effect of leukocytes on transplantability of human cancer","volume":"19","author":"Southam","year":"1966","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1038\/ncomms8458","article-title":"Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","article-title":"Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor","volume":"116","author":"Jena","year":"2010","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcyt.2015.09.011","article-title":"Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies","volume":"18","author":"Masuyama","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11899-019-00528-6","article-title":"Induced pluripotent stem cell (iPSC)-derived lymphocytes for adoptive cell immunotherapy: Recent advances and challenges","volume":"14","author":"Nianias","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fimmu.2017.00755","article-title":"\u00c1ngel; Borrego, F.; Eguizabal, C. OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors","volume":"8","author":"Herrera","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yasuda, S., Kusakawa, S., Kuroda, T., Miura, T., Tano, K., Takada, N., Matsuyama, S., Matsuyama, A., Nasu, M., and Umezawa, A. (2018). Tumorigenicity-associated characteristics of human iPS cell lines. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205022"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-2005-872520","article-title":"Ex vivo Expansion of Highly Purified NK Cells for Immunotherapy after Haploidentical Stem Cell Transplantation in Children","volume":"217","author":"Koehl","year":"2005","journal-title":"Klinische P\u00e4diatrie"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fimmu.2019.00879","article-title":"Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21","volume":"10","author":"Kweon","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2013.00118","article-title":"Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol","volume":"3","author":"Koehl","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","article-title":"A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer","volume":"59","author":"Iliopoulou","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Li, S., Gong, T., Kou, C., Fu, A., Bolanos, R., and Liu, J. (2021). Clinical Outcomes Associated With Chronic Kidney Disease in Elderly Medicare Patients with Multiple Myeloma. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2021.01.015"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"106498","DOI":"10.1016\/j.leukres.2020.106498","article-title":"Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study","volume":"101","author":"Shragai","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0889-8588(05)70435-4","article-title":"Pathogenesis and management of bone lesions in multiple myeloma","volume":"11","author":"Bataille","year":"1997","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leuk."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2019.1648806","article-title":"Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: An indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials","volume":"61","author":"Weisel","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Kararoudi","year":"2020","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/967\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:50:41Z","timestamp":1760161841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":74,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cells10050967"],"URL":"https:\/\/doi.org\/10.3390\/cells10050967","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]}}}